Physician profile
Michael S Grable
NPI 1588614374
$20,103.31
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,039 · 2021: $2,602 · 2022: $1,194 · 2023: $1,164 · 2024: $20.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,112.94 | 2019-2023 | Erleada |
| Urogpo LLC | $4,181.90 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,024.25 | 2019-2023 | |
| Astellas Pharma US INC | $1,330.96 | 2019-2023 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $787.41 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $381.51 | 2019-2023 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $338.09 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $252.29 | 2020-2023 | Lynparza |
| Abbvie INC. | $221.45 | 2019-2023 | |
| Pfizer INC. | $220.17 | 2019-2022 | |
| Boston Scientific Corporation | $214.63 | 2019-2022 | |
| Cook Medical LLC | $189.89 | 2019-2021 | |
| Amgen INC. | $166.45 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $163.22 | 2021-2023 | Prolaris |
| Allergan, INC. | $152.95 | 2019-2021 |
Show all 47 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.